vs

Side-by-side financial comparison of IMAX CORP (IMAX) and MYRIAD GENETICS INC (MYGN). Click either name above to swap in a different company.

MYRIAD GENETICS INC is the larger business by last-quarter revenue ($209.8M vs $125.2M, roughly 1.7× IMAX CORP). On growth, IMAX CORP posted the faster year-over-year revenue change (35.1% vs -0.4%). Over the past eight quarters, IMAX CORP's revenue compounded faster (25.8% CAGR vs 1.9%).

IMAX Corporation is a Canadian production theatre company which designs and manufactures IMAX cameras and projection systems as well as performing film development, production, post-production and distribution to IMAX-affiliated theatres worldwide. Founded in Montreal in 1967, it has headquarters in the Toronto area, and operations in New York City and Los Angeles.

Myriad Genetics, Inc. is an American genetic testing and precision medicine company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new products that assess an individual's risk for developing disease later in life, identify a pati...

IMAX vs MYGN — Head-to-Head

Bigger by revenue
MYGN
MYGN
1.7× larger
MYGN
$209.8M
$125.2M
IMAX
Growing faster (revenue YoY)
IMAX
IMAX
+35.5% gap
IMAX
35.1%
-0.4%
MYGN
Faster 2-yr revenue CAGR
IMAX
IMAX
Annualised
IMAX
25.8%
1.9%
MYGN

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
IMAX
IMAX
MYGN
MYGN
Revenue
$125.2M
$209.8M
Net Profit
$637.0K
Gross Margin
57.6%
70.0%
Operating Margin
19.3%
-2.7%
Net Margin
0.5%
Revenue YoY
35.1%
-0.4%
Net Profit YoY
-88.0%
EPS (diluted)
$0.02
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IMAX
IMAX
MYGN
MYGN
Q4 25
$125.2M
$209.8M
Q3 25
$106.7M
$205.7M
Q2 25
$91.7M
$213.1M
Q1 25
$86.7M
$195.9M
Q4 24
$92.7M
$210.6M
Q3 24
$91.5M
$213.3M
Q2 24
$89.0M
$211.5M
Q1 24
$79.1M
$202.2M
Net Profit
IMAX
IMAX
MYGN
MYGN
Q4 25
$637.0K
Q3 25
$20.7M
$-27.4M
Q2 25
$11.3M
$-330.5M
Q1 25
$2.3M
$-100.0K
Q4 24
$5.3M
Q3 24
$13.9M
$-22.1M
Q2 24
$3.6M
$-36.7M
Q1 24
$3.3M
$-26.0M
Gross Margin
IMAX
IMAX
MYGN
MYGN
Q4 25
57.6%
70.0%
Q3 25
63.1%
69.9%
Q2 25
58.5%
71.2%
Q1 25
61.4%
68.5%
Q4 24
52.2%
71.7%
Q3 24
55.8%
70.2%
Q2 24
49.4%
69.6%
Q1 24
59.3%
68.1%
Operating Margin
IMAX
IMAX
MYGN
MYGN
Q4 25
19.3%
-2.7%
Q3 25
27.2%
-11.3%
Q2 25
15.6%
-154.5%
Q1 25
19.3%
-14.8%
Q4 24
10.3%
-18.6%
Q3 24
21.2%
-9.4%
Q2 24
3.2%
-17.3%
Q1 24
15.3%
-13.8%
Net Margin
IMAX
IMAX
MYGN
MYGN
Q4 25
0.5%
Q3 25
19.4%
-13.3%
Q2 25
12.3%
-155.1%
Q1 25
2.7%
-0.1%
Q4 24
5.7%
Q3 24
15.2%
-10.4%
Q2 24
4.0%
-17.4%
Q1 24
4.1%
-12.9%
EPS (diluted)
IMAX
IMAX
MYGN
MYGN
Q4 25
$0.02
$-0.09
Q3 25
$0.37
$-0.29
Q2 25
$0.20
$-3.57
Q1 25
$0.04
$0.00
Q4 24
$0.09
$-0.47
Q3 24
$0.26
$-0.24
Q2 24
$0.07
$-0.41
Q1 24
$0.06
$-0.29

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IMAX
IMAX
MYGN
MYGN
Cash + ST InvestmentsLiquidity on hand
$151.2M
$149.6M
Total DebtLower is stronger
$119.9M
Stockholders' EquityBook value
$337.9M
$368.0M
Total Assets
$894.0M
$706.6M
Debt / EquityLower = less leverage
0.33×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IMAX
IMAX
MYGN
MYGN
Q4 25
$151.2M
$149.6M
Q3 25
$143.1M
$145.4M
Q2 25
$109.3M
$74.4M
Q1 25
$97.1M
$91.8M
Q4 24
$100.6M
$102.4M
Q3 24
$104.5M
$99.9M
Q2 24
$91.6M
$97.3M
Q1 24
$81.0M
$104.3M
Total Debt
IMAX
IMAX
MYGN
MYGN
Q4 25
$119.9M
Q3 25
$119.5M
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
IMAX
IMAX
MYGN
MYGN
Q4 25
$337.9M
$368.0M
Q3 25
$349.5M
$372.8M
Q2 25
$320.4M
$388.1M
Q1 25
$299.5M
$704.9M
Q4 24
$299.5M
$701.1M
Q3 24
$289.4M
$731.7M
Q2 24
$267.2M
$740.5M
Q1 24
$258.8M
$760.0M
Total Assets
IMAX
IMAX
MYGN
MYGN
Q4 25
$894.0M
$706.6M
Q3 25
$889.6M
$728.1M
Q2 25
$868.6M
$677.3M
Q1 25
$848.3M
$1.0B
Q4 24
$830.4M
$1.0B
Q3 24
$847.6M
$1.1B
Q2 24
$827.4M
$1.1B
Q1 24
$824.1M
$1.1B
Debt / Equity
IMAX
IMAX
MYGN
MYGN
Q4 25
0.33×
Q3 25
0.32×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IMAX
IMAX
MYGN
MYGN
Operating Cash FlowLast quarter
$29.4M
$10.6M
Free Cash FlowOCF − Capex
$28.0M
FCF MarginFCF / Revenue
22.3%
Capex IntensityCapex / Revenue
1.1%
Cash ConversionOCF / Net Profit
46.11×
TTM Free Cash FlowTrailing 4 quarters
$118.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IMAX
IMAX
MYGN
MYGN
Q4 25
$29.4M
$10.6M
Q3 25
$67.5M
$21.1M
Q2 25
$23.2M
$-13.6M
Q1 25
$7.0M
$-16.3M
Q4 24
$11.5M
$6.6M
Q3 24
$35.3M
$700.0K
Q2 24
$35.0M
$2.6M
Q1 24
$-11.0M
$-18.6M
Free Cash Flow
IMAX
IMAX
MYGN
MYGN
Q4 25
$28.0M
Q3 25
$64.8M
Q2 25
$20.9M
Q1 25
$5.3M
Q4 24
$6.9M
Q3 24
$34.2M
Q2 24
$33.5M
Q1 24
$-12.1M
FCF Margin
IMAX
IMAX
MYGN
MYGN
Q4 25
22.3%
Q3 25
60.7%
Q2 25
22.8%
Q1 25
6.1%
Q4 24
7.4%
Q3 24
37.3%
Q2 24
37.6%
Q1 24
-15.3%
Capex Intensity
IMAX
IMAX
MYGN
MYGN
Q4 25
1.1%
Q3 25
2.6%
Q2 25
2.6%
Q1 25
1.9%
Q4 24
5.0%
Q3 24
1.2%
Q2 24
1.8%
Q1 24
1.4%
Cash Conversion
IMAX
IMAX
MYGN
MYGN
Q4 25
46.11×
Q3 25
3.27×
Q2 25
2.06×
Q1 25
2.99×
Q4 24
2.16×
Q3 24
2.54×
Q2 24
9.78×
Q1 24
-3.35×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IMAX
IMAX

Technology Sales$46.6M37%
Image Enhancement And Maintenance Services$38.1M30%
Joint Revenue Sharing Arrangement$20.4M16%
Maintenance$16.3M13%
Finance Income$2.8M2%
Other Content Solutions$1.6M1%

MYGN
MYGN

Segment breakdown not available.

Related Comparisons